COVID-19 and diabetes mellitus: from pathophysiology to clinical management.
Reads0
Chats0
TLDR
Evidence suggests that insulin and dipeptidyl peptidase 4 inhibitors can be used safely in patients with diabetes mellitus and COVID-19; metformin and sodium–glucose cotransporter 2 inhibitors might need to be withdrawn in patients at high risk of severe disease.Abstract:
Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients with diabetes mellitus. Furthermore, COVID-19 might also predispose infected individuals to hyperglycaemia. Interacting with other risk factors, hyperglycaemia might modulate immune and inflammatory responses, thus predisposing patients to severe COVID-19 and possible lethal outcomes. Angiotensin-converting enzyme 2 (ACE2), which is part of the renin-angiotensin-aldosterone system (RAAS), is the main entry receptor for SARS-CoV-2; although dipeptidyl peptidase 4 (DPP4) might also act as a binding target. Preliminary data, however, do not suggest a notable effect of glucose-lowering DPP4 inhibitors on SARS-CoV-2 susceptibility. Owing to their pharmacological characteristics, sodium-glucose cotransporter 2 (SGLT2) inhibitors might cause adverse effects in patients with COVID-19 and so cannot be recommended. Currently, insulin should be the main approach to the control of acute glycaemia. Most available evidence does not distinguish between the major types of diabetes mellitus and is related to type 2 diabetes mellitus owing to its high prevalence. However, some limited evidence is now available on type 1 diabetes mellitus and COVID-19. Most of these conclusions are preliminary, and further investigation of the optimal management in patients with diabetes mellitus is warranted.read more
Citations
More filters
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou,Ting Yu,Ronghui Du,Guohui Fan,Ying Liu,Zhibo Liu,Jie Xiang,Yeming Wang,Bin Song,Xiaoying Gu,Xiaoying Gu,Lulu Guan,Yuan Wei,Li Hui,Xudong Wu,Jiuyang Xu,Shengjin Tu,Yi Zhang,Hua Chen,Bin Cao +19 more
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Journal ArticleDOI
Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda,Kate Maclagan,Simon S. Skene,Martha Bajwa-Joseph,Dawn Letchford,Kashfia Chowdhury,Steve Hibbert,Natalia Budnik,Luca Zampedri,John Dickson,Yazhou Li,Iciar Aviles-Olmos,Thomas T. Warner,Patricia Limousin,Andrew J. Lees,Nigel H. Greig,Susan Tebbs,Thomas Foltynie +17 more
TL;DR: Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure, and effects on everyday symptoms should be examined in longer-term trials.
Journal ArticleDOI
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning.
TL;DR: The increased prevalence of obesity, diabetes, and cardiovascular risk factors in people hospitalized with severe COVID-19 illness has engendered considerable interest in the metabolic aspects of SARS-CoV-2-induced pathophysiology as mentioned in this paper.
Journal ArticleDOI
Clinical Characteristics of COVID-19
TL;DR: Though COVID-19 mainly affects the respiratory system, disease may cause widespread systemic and organ specific symptoms involving gastrointestinal, neurological, cardiovascular, immunological, cutaneous, hematological and coagulation systems.
Journal ArticleDOI
ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries.
Shivaprakash M Rudramurthy,Martin Hoenigl,Martin Hoenigl,Jacques F. Meis,Oliver A. Cornely,Valliappan Muthu,Jean-Pierre Gangneux,John R. Perfect,Arunaloke Chakrabarti,Ecmm,Isham +10 more
TL;DR: In this article, the authors provided a comprehensive document to help clinicians in managing COVID-19-associated mucormycosis (CAM) globally, driven particularly by low and middle-income countries.
References
More filters
Journal ArticleDOI
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19.
Yan Zhang,Meng Xiao,Shulan Zhang,Peng Xia,Wei Cao,Wei Jiang,Huan Chen,Xin Ding,Hua Zhao,Hongmin Zhang,Chunyao Wang,Jing Zhao,Xuefeng Sun,Ran Tian,Wei Wu,Dong Wu,Jie Ma,Yu Chen,Dong Zhang,Jing Xie,Xiaowei Yan,Xiang Zhou,Zhengyin Liu,Jinglan Wang,Bin Du,Yan Qin,Peng Gao,Xuzhen Qin,Yingchun Xu,Wen Zhang,Taisheng Li,Fengchun Zhang,Yongqiang Zhao,Yongzhe Li,Shuyang Zhang +34 more
TL;DR: A 69-year-old man with Covid-19 diagnosed in January 2020 in Wuhan, China, along with two other critically ill patients with Covod-19 who were also seen in the same intensive care unit are described.
Journal ArticleDOI
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis.
Sterne Jac.,Srinivas Murthy,Janet V. Diaz,Arthur S. Slutsky,Judit Villar,Derek C. Angus,Djillali Annane,Azevedo Lcp.,Otavio Berwanger,Alexandre Biasi Cavalcanti,Dequin P-F.,Dequin P-F.,Bin Du,Jonathan Emberson,David Fisher,Bruno Giraudeau,Anthony C. Gordon,Anders Granholm,Cameron Green,Richard Haynes,N Heming,Higgins Jpt.,Higgins Jpt.,Peter Horby,Peter Jüni,Martin J Landray,A. Le Gouge,Marie Leclerc,Wei Shen Lim,Flávia Ribeiro Machado,Colin McArthur,Colin McArthur,Ferhat Meziani,Morten Hylander Møller,Anders Perner,M W Petersen,Jelena Savović,Jelena Savović,Bruno Martins Tomazini,Viviane C Veiga,Steven A R Webb,John C. Marshall +41 more
TL;DR: A prospective meta-analysis that pooled data from 7 randomized clinical trials that evaluated the efficacy of corticosteroids in 1703 critically ill patients with COVID-19 found that low-dose dexamethasone reduced mortality in hospitalized patients with Cohen's disease who required respiratory support.
Journal ArticleDOI
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
V. Stalin Raj,Huihui Mou,Saskia L. Smits,Dick H. W. Dekkers,Marcel A. Müller,Ronald Dijkman,Doreen Muth,Jeroen Demmers,Ali Moh Zaki,Ron A. M. Fouchier,Volker Thiel,Volker Thiel,Christian Drosten,Peter J. M. Rottier,Albert D. M. E. Osterhaus,Berend Jan Bosch,Bart L. Haagmans +16 more
TL;DR: Dipeptidyl peptidase 4 (DPP4; also known as CD26) is identified as a functional receptor for hCoV-EMC and will contribute critically to the understanding of the pathogenesis and epidemiology of this emerging human coronavirus, and may facilitate the development of intervention strategies.
Journal ArticleDOI
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
Muthiah Vaduganathan,Orly Vardeny,Thomas Michel,John J.V. McMurray,Marc A. Pfeffer,Scott D. Solomon +5 more
TL;DR: RAAS Inhibitors in Patients with Covid-19 show low levels of renin–angiotensin-converting enzyme 2 levels and activity in humans, but the effects are still uncertain.
Journal ArticleDOI
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Qian Zhang,Paul Bastard,Paul Bastard,Zhiyong Liu,Jérémie Le Pen,Marcela Moncada-Vélez,Jie Chen,Masato Ogishi,Ira K. D. Sabli,Stephanie Hodeib,Cecilia B. Korol,Jérémie Rosain,Jérémie Rosain,Kaya Bilguvar,Junqiang Ye,Alexandre Bolze,Benedetta Bigio,Rui Yang,Andrés Augusto Arias,Andrés Augusto Arias,Qinhua Zhou,Yu Zhang,Fanny Onodi,Sarantis Korniotis,Léa Karpf,Quentin Philippot,Quentin Philippot,Marwa Chbihi,Marwa Chbihi,Lucie Bonnet-Madin,Karim Dorgham,Nikaïa Smith,William M. Schneider,Brandon S. Razooky,Hans-Heinrich Hoffmann,Eleftherios Michailidis,Leen Moens,Ji Eun Han,Lazaro Lorenzo,Lazaro Lorenzo,Lucy Bizien,Lucy Bizien,Philip Meade,Anna-Lena Neehus,Anna-Lena Neehus,Aileen Camille Ugurbil,Aurélien Corneau,Gaspard Kerner,Gaspard Kerner,Peng Zhang,Franck Rapaport,Yoann Seeleuthner,Yoann Seeleuthner,Jeremy Manry,Jeremy Manry,Cécile Masson,Yohann Schmitt,Agatha Schlüter,Tom Le Voyer,Tom Le Voyer,Taushif Khan,Juan Li,Jacques Fellay,Jacques Fellay,Lucie Roussel,Mohammad Shahrooei,Mohammed F. Alosaimi,Davood Mansouri,Haya Al-Saud,Fahd Al-Mulla,Feras M. Almourfi,Saleh Al-Muhsen,Fahad Alsohime,Saeed Al Turki,Rana Hasanato,Diederik van de Beek,Andrea Biondi,Laura Rachele Bettini,Mariella D'Angiò,Paolo Bonfanti,Luisa Imberti,Alessandra Sottini,Simone Paghera,Eugenia Quiros-Roldan,Camillo Rossi,Andrew J. Oler,Miranda F. Tompkins,Camille Alba,Isabelle Vandernoot,Jean-Christophe Goffard,Guillaume Smits,Isabelle Migeotte,Filomeen Haerynck,Pere Soler-Palacín,Andrea Martín-Nalda,Roger Colobran,Pierre-Emmanuel Morange,Sevgi Keles,Fatma Çölkesen,Tayfun Ozcelik,Kadriye Kart Yaşar,Sevtap Şenoğlu,Şemsi Nur Karabela,Carlos Rodríguez-Gallego,Giuseppe Novelli,Sami Hraiech,Yacine Tandjaoui-Lambiotte,Xavier Duval,Xavier Duval,Cédric Laouénan,Cédric Laouénan,Covid-Storm Clinicians§,Covid Clinicians,CoV-Contact Cohort§,CoV-Contact Cohort§,Amsterdam Umc Covid Biobank,Covid Human Genetic Effort,Niaid-Usuhs,Niaid-Usuhs,Niaid-Usuhs,Andrew L. Snow,Clifton L. Dalgard,Joshua D. Milner,Donald C. Vinh,Donald C. Vinh,Trine H. Mogensen,Trine H. Mogensen,Nico Marr,András N Spaan,András N Spaan,András N Spaan,Bertrand Boisson,Bertrand Boisson,Bertrand Boisson,Stéphanie Boisson-Dupuis,Jacinta Bustamante,Jacinta Bustamante,Jacinta Bustamante,Anne Puel,Michael J. Ciancanelli,Isabelle Meyts,Tom Maniatis,Vassili Soumelis,Ali Amara,Ali Amara,Michel C. Nussenzweig,Adolfo García-Sastre,Florian Krammer,Aurora Pujol,Darragh Duffy,Darragh Duffy,Richard P. Lifton,Richard P. Lifton,Richard P. Lifton,Shen-Ying Zhang,Guy Gorochov,Guy Gorochov,Guy Gorochov,Vivien Béziat,Vivien Béziat,Vivien Béziat,Emmanuelle Jouanguy,Vanessa Sancho-Shimizu,Charles M. Rice,Charles M. Rice,Charles M. Rice,Laurent Abel,Luigi D. Notarangelo,Luigi D. Notarangelo,Luigi D. Notarangelo,Aurélie Cobat,Helen C. Su,Jean-Laurent Casanova +172 more
TL;DR: The COVID Human Genetic Effort established to test the general hypothesis that life-threatening COVID-19 in some or most patients may be caused by monogenic inborn errors of immunity to SARS-CoV-2 with incomplete or complete penetrance finds an enrichment in variants predicted to be loss-of-function (pLOF), with a minor allele frequency <0.001.
Related Papers (5)
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.
Lihua Zhu,Zhi-Gang She,Xu Cheng,Juan Juan Qin,Xiao Jing Zhang,Jingjing Cai,Fang Lei,Haitao Wang,Jing Xie,Wenxin Wang,Haomiao Li,Peng Zhang,Xiaohui Song,Xi Chen,Xiang Mei,Chaozheng Zhang,Liangjie Bai,Da Xiang,Ming Ming Chen,Yanqiong Liu,Youqin Yan,Mingyu Liu,Weiming Mao,Jinjing Zou,Liming Liu,Guohua Chen,Pengcheng Luo,Bing Xiao,Changjiang Zhang,Zixiong Zhang,Zhigang Lu,Junhai Wang,Haofeng Lu,Xigang Xia,Daihong Wang,Xiaofeng Liao,Gang Peng,Ping Ye,Jun Yang,Yufeng Yuan,Xiaodong Huang,Jiao Guo,Bing Hong Zhang,Hongliang Li +43 more
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
Zunyou Wu,Jennifer M. McGoogan +1 more
Clinical Characteristics of Coronavirus Disease 2019 in China.
Wei-jie Guan,Zhengyi Ni,Yu Hu,Wenhua Liang,Chun-Quan Ou,Jianxing He,Lei Liu,Hong Shan,Chunliang Lei,David S.C. Hui,Bin Du,Lanjuan Li,Guang Zeng,Kowk-Yung Yuen,Ruchong Chen,Chun-Li Tang,Tao Wang,Ping-Yan Chen,Jie Xiang,Shiyue Li,Jinlin Wang,Zi-jing Liang,Yi-xiang Peng,Li Wei,Yong Liu,Ya-hua Hu,Peng Peng,Jian-ming Wang,Ji-yang Liu,Zhong Chen,Gang Li,Zhi-jian Zheng,Shao-qin Qiu,Jie Luo,Chang-jiang Ye,Shao-yong Zhu,Nanshan Zhong +36 more